Claims
- 1. A purified IgG monoclonal antibody that binds selectively to poly(ethylene glycol).
- 2. A purified IgG monoclonal antibody fragment that binds selectively to poly(ethylene glycol).
- 3 The antibody fragment of claim 2, wherein the fragment is a F(ab′)2, Fab, or Fv fragment.
- 4. The antibody of claim 1, wherein said antibody comprises the VL region amino acid sequence set forth in SEQ ID NO: 1.
- 5. The antibody of claim 1, wherein said antibody comprises the VH region amino acid sequence set forth in SEQ ID NO: 2.
- 6. The antibody of claim 1, wherein said antibody comprises at least one light chain having an amino acid sequence having at least about 70% sequence identity to the amino acid sequence set forth in SEQ ID NO:1 and at least one heavy chain having at least about 70% sequence identity to the amino acid sequence set forth in SEQ ID NO:2.
- 7. The antibody of claim 6, wherein said antibody comprises at least one light chain having an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:1 and at least one heavy chain having at least about 80% sequence identity to SEQ ID NO:2.
- 8. The antibody of claim 7, wherein said antibody comprises at least one light chain having an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1 and at least one heavy chain having at least about 90% sequence identity to SEQ ID NO:2.
- 9. The antibody of claim 8, wherein said antibody comprises at least one light chain having an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:1 and at least one heavy chain having at least about 95% sequence identity to SEQ ID NO:2.
- 10. The purified IgG monoclonal antibody of claim 1, wherein said antibody is humanized.
- 11. The antibody of claim 1, wherein said antibody is a human antibody.
- 12. A molecule comprising the antibody of claim 1 and a detectable label group.
- 13. A polynucleotide comprising a contiguous series of nucleotides selected from the group consisting of:
a) the contiguous series of nucleotides set forth in SEQ ID NO:3; b) the contiguous series of nucleotides set forth in SEQ ID NO:4; c) a contiguous series of nucleotides encoding the light chain variable region amino acid sequence set forth in SEQ ID NO:1; d) a contiguous series of nucleotides encoding the heavy chain variable region amino acid sequence set forth in SEQ ID NO:2; e) a polynucleotide encoding a polypeptide having at least about 70% sequence identity with the amino acid sequence set forth in SEQ ID NO:1; and f) a polynucleotide encoding a polypeptide comprising an amino acid sequence having at least about 70% sequence identity with the amino acid sequence of SEQ ID NO:2.
- 14. An expression vector comprising a polynucleotide of claim 13.
- 15. A host cell comprising the expression vector of claim 14.
- 16. A hybridoma cell line that produces a monoclonal IgG antibody that binds selectively to PEG.
- 17. The hybridoma cell line of claim 16, wherein said cell line is the cell line deposited with the ATCC as Patent Deposit Number PTA-4112.
- 18. A purified IgG monoclonal antibody that binds to the same epitope as the monoclonal antibody produced by the hybridoma cell line deposited with ATCC as Patent Deposit Number PTA-4112.
- 19. The antibody produced by the hybridoma cell line of claim 17.
- 20. A method of producing the monoclonal IgG antibody of claim 1 comprising culturing a host cell that expresses said antibody.
- 21. A purified IgG monoclonal antibody produced by the method of claim 20.
- 22. The purified monoclonal IgG antibody of claim 21, wherein said purified monoclonal antibody is humanized.
- 23. The purified monoclonal IgG antibody of claim 22, wherein said purified monoclonal antibody is a human antibody.
- 24. A purified monoclonal IgG antibody produced according to the method of claim 20, wherein said purified IgG monoclonal antibody has a detectable label bound thereto.
- 25. A composition comprising the monoclonal IgG antibody of claim 1 and a pharmaceutically acceptable carrier.
- 26. A method for detecting a target comprising at least one poly(ethylene glycol) group, the method comprising:
(a) contacting said target with the purified IgG monoclonal antibody of claim 1 under conditions such that the antibody can bind to the target; and (b) detecting a complex formed by the binding of said antibody to said target.
- 27. The method of claim 26, wherein said detecting step comprises performing an immunoassay.
- 28. The method of claim 27, wherein said antibody is attached to a solid support.
- 29. A method for purifying a target that comprises at least one poly(ethylene glycol) group, the method comprising the steps of:
(a) contacting the target with the antibody of claim 1 under conditions such that the antibody binds to the target; and (b) recovering a complex containing the antibody and the bound target.
- 30. The method of claim 29, wherein the target is selected from the group consisting of peptides, proteins, enzymes, cytokines, hematopoietins, growth factors, hormones, antigens, antibodies, antibody fragments, receptors, protein fragments, drugs, dyes, nucleotides, oligonucleotides, saccharides, polysaccharides, natural polymers, synthetic polymers, lipids, and phospholipids.
- 31. A method for modulating the number of poly(ethylene glycol) group-containing molecules circulating in a subject, the method comprising the step of administering the purified IgG monoclonal antibody of claim 1 to the subject.
- 32. The method of claim 31, whereby as a result of said administering the number of poly(ethylene glycol) group-containing molecules is decreased.
- 33. The method of claim 31, whereby as a result of said administering the number of poly(ethylene glycol) group-containing molecules is increased.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of Provisional Application Serial No. 60/292,371, filed May 21, 2001, which is incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60292371 |
May 2001 |
US |